Enlitic (ASX:ENL) ROE %: -177.78% (As of Dec. 2025)


What is Enlitic ROE %?

Enlitic ASX:ENL -16.67% ROE % is -177.78% as of Dec. 2025. The stock has 2 warning signs investors should review. Among 628 Healthcare Providers & Services companies, Enlitic ranks worse than 95.38% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Enlitic's annualized net income for the quarter that ended in Dec. 2025 was A$-19.60 Mil. Enlitic's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was A$11.03 Mil. Therefore, Enlitic's annualized ROE % for the quarter that ended in Dec. 2025 was -177.78%.

The historical rank and industry rank for Enlitic's ROE % or its related term are showing as below:

ASX:ENL' s ROE % Range Over the Past 10 Years
Min: -170.95   Med: -142.55   Max: -142.15
Current: -154.63

During the past 3 years, Enlitic's highest ROE % was -142.15%. The lowest was -170.95%. And the median was -142.55%.

ASX:ENL's ROE % is ranked worse than
95.38% of 628 companies
in the Healthcare Providers & Services industry
Industry Median: 5.72 vs ASX:ENL: -154.63

Enlitic  (ASX:ENL) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=-19.602/11.026
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-19.602 / 5.74)*(5.74 / 17.956)*(17.956 / 11.026)
=Net Margin %*Asset Turnover*Equity Multiplier
=-341.5 %*0.3197*1.6285
=ROA %*Equity Multiplier
=-109.18 %*1.6285
=-177.78 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=-19.602/11.026
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-19.602 / -19.59) * (-19.59 / -19.538) * (-19.538 / 5.74) * (5.74 / 17.956) * (17.956 / 11.026)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0006 * 1.0027 * -340.38 % * 0.3197 * 1.6285
=-177.78 %

Note: The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.

Enlitic ROE % Related Terms

Enlitic ROE % Historical Data

* Premium members only.

The historical data trend for Enlitic's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enlitic ROE % Chart

Enlitic Annual Data
Trend Dec23 Dec24 Dec25
ROE %
-142.15 -142.55 -170.95

Enlitic Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
ROE % 0.00 -183.51 -225.15 -126.50 -177.78

ASX:ENL vs VEEV, BTSG, TEM: ROE % Comparison

For the Health Information Services subindustry, Enlitic's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enlitic ROE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Enlitic's ROE % distribution charts can be found below:

* The bar in red indicates where Enlitic's ROE % falls into.


Enlitic ROE % Calculation

Enlitic's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=-20.128/( (17.413+6.136)/ 2 )
=-20.128/11.7745
=-170.95 %

Enlitic's annualized ROE % for the quarter that ended in Dec. 2025 is calculated as

ROE %=Net Income (Q: Dec. 2025 )/( (Total Stockholders Equity (Q: Jun. 2025 )+Total Stockholders Equity (Q: Dec. 2025 ))/ count )
=-19.602/( (15.916+6.136)/ 2 )
=-19.602/11.026
=-177.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2025) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of -177.78% mean?
Enlitic (ASX:ENL) has a ROE % of -177.78% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Enlitic and its competitors. According to the industry distribution chart, Enlitic ranks #599 out of 628 companies in the Healthcare Providers & Services industry, placing it in the top 95.4%.
Is Enlitic's ROE % too high?
Enlitic's current ROE % is -177.78%. Based on the distribution chart, Enlitic ranks #599 out of 628 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Enlitic's ROE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Enlitic ranks #599 out of 628 companies for ROE %. This places Enlitic in the lower half of its industry. The industry median ROE % is 5.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.72, based on 628 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Enlitic and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enlitic's current ROE % is -177.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enlitic stock overvalued right now?
Enlitic (ASX:ENL) has a current ROE % of -177.78%. The current ROE % is -177.78%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Enlitic (ASX:ENL), the current ROE % is -177.78% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enlitic Business Description

Address 1635 Foxtrail Drive, Suite 111A, Loveland, CO, USA, 80538
Enlitic Inc is the AI-enabled healthcare revolution. The company has developed an intelligent data framework that powers critical workflows, orchestrates data, and enables greater comprehension of what information resides in archives thereby unlocking new revenue opportunities, generating cost savings, and improving healthcare delivery. It provides solutions for Radiologists, IT Professionals, Executives, and Researchers. The Group has two operating segments: Software includes intelligently managing healthcare data using the power of artificial intelligence to expand capacity and improve clinical workflows, etc; and Migration services Transfer large volumes of imaging data to allow for the smooth transition of software solutions for healthcare vendors and providers and Migration services.